keyword
https://read.qxmd.com/read/38567897/a-heart-transplant-center-experience-with-basiliximab-induction-strategies-a-double-edged-sword
#21
JOURNAL ARTICLE
Luise Holzhauser, Maxwell Norris, Maria Molina, Susan Chambers, Swethika Sundaravel, Eman Rashed, Ketan Gala, Tara Fallah, Therese Bittermann, Nosheen Reza, Teresa Wang, Pavan Atluri, Lee Goldberg, Rhondalyn McLean, Eliot Peyster
BACKGROUND: The use of induction immunosuppression for heart transplantation (HT) is debated given the uncertain benefit and potential risks of infection and malignancy. METHODS: This is a retrospective single-center analysis of 475 consecutive HT recipients from 2003 to 2020 grouped by use of induction with basiliximab group (BG) and the no basiliximab group (NBG). Subgroup analysis by era compared pre-2016 standard-basiliximab (BX) induction and 2016-2020 with selective-BX use as part of a calcineurin-inhibitor-sparing regimen...
April 2024: Clinical Transplantation
https://read.qxmd.com/read/38566573/consideration-for-alpha-gal-syndrome-in-two-critically-ill-persons-with-group-o-blood-who-received-group-b-plasma
#22
Maureen J Miller, Patricia Lee, Brian G Lee, Willy A Flegel, Kamille West-Mitchell, Kathleen Conry-Cantilena, Valeria De Giorgi
BACKGROUND: The U.S. Centers for Disease Control and Prevention (CDC) has reported increasing rates of alpha-gal syndrome, an allergic response after meat ingestion (AGS). AGS has been associated with prior exposure to tick bites or other biologics characterized by a life-threatening immunoglobulin E (IgE)-mediated hypersensitivity to galactose-alpha-1,3-galactose (alpha-gal) an oligosaccharide structurally similar to the group B antigen on red blood cells (RBC) found in most non-primate mammalian meat and products derived from these mammals...
April 3, 2024: Transfusion
https://read.qxmd.com/read/38565406/a-novel-fk506-loading-mesoporous-silica-nanoparticle-homing-to-lymph-nodes-for-transplant-rejection-treatment
#23
JOURNAL ARTICLE
Yishu Song, Qiaofeng Jin, Binqian Zhou, Cheng Deng, Wuqi Zhou, Wenqu Li, Luyang Yi, Mengdan Ding, Yihan Chen, Tang Gao, Li Zhang, Mingxing Xie
Tacrolimus (FK506) is an effective therapeutic for transplant rejection in clinical practice, primarily inhibiting rejection by suppressing the activation and proliferation of allogeneic T cells in the lymph nodes (LNs). However, conventional administration methods face challenges in directly delivering free FK506 to the LNs. In this study, we introduce a novel LN-targeted delivery system based on mesoporous silica nanoparticles (MSNs-FK506-MECA79). These particles were designed to selectively target high endothelial venules in LNs; this was achieved through surface modification with MECA79 antibodies...
March 31, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38563698/rare-complications-of-heart-transplant-autopsy-findings
#24
JOURNAL ARTICLE
Devika Gupta, Lavan Singh, Sameer Kumar, Kanwaljeet Singh, Satish Mendonca, Tathagat Chatterjee
BACKGROUND: Heart transplantation has evolved as the only treatment option for patients with refractory heart failure. CASE PRESENTATION: We here, report two unusual complications that developed following cardiac transplant to which the recipients succumbed. Post mortem conducted revealed the cause of death as severe antibody mediated rejection in one case and ruptured mycotic aneurysm of ascending aorta in the second recipient. CONCLUSION: Hence, autopsy remains the key procedure that can help establish the cause of death after cardiac transplant...
March 25, 2024: Indian Journal of Pathology & Microbiology
https://read.qxmd.com/read/38561059/anti-icam-1-mono-maintenance-therapy-induced-long-term-liver-allograft-survival-without-chronic-rejection
#25
JOURNAL ARTICLE
Dong Kyu Han, Suk Kyun Hong, Il Hee Yun, Ji-Jing Yan, Jisu Park, Sang Wha Kim, Seung Hyeok Seok, Haeryoung Kim, Gilyong Ji, YoungRok Choi, Kwang-Woong Lee, Kyung-Suk Suh, Jaeseok Yang, Nam-Joon Yi
Calcineurin inhibitors (CNIs) are essential in liver transplantation (LT); however, their long-term use leads to various adverse effects. The anti-intercellular adhesion molecule-1 (ICAM-1) monoclonal antibody MD3 is a potential alternative to CNI. Despite its promising results with short-term therapy, overcoming the challenge of chronic rejection remains important. Thus, we aimed to investigate the outcomes of long-term MD3 therapy with monthly MD3 mono-maintenance in nonhuman primate LT models. Rhesus macaques underwent major histocompatibility complex-mismatched allogeneic LT...
March 30, 2024: American Journal of Transplantation
https://read.qxmd.com/read/38558788/targeted-drug-delivery-of-engineered-mesenchymal-stem-stromal-cell-derived-exosomes-in-cardiovascular-disease-recent-trends-and-future-perspectives
#26
REVIEW
Jian-Liang Pang, Hong Shao, Xiao-Gang Xu, Zhi-Wei Lin, Xiao-Yi Chen, Jin-Yang Chen, Xiao-Zhou Mou, Pei-Yang Hu
In recent years, stem cells and their secretomes, notably exosomes, have received considerable attention in biomedical applications. Exosomes are cellular secretomes used for intercellular communication. They perform the function of intercellular messengers by facilitating the transport of proteins, lipids, nucleic acids, and therapeutic substances. Their biocompatibility, minimal immunogenicity, targetability, stability, and engineerable characteristics have additionally led to their application as drug delivery vehicles...
2024: Frontiers in Bioengineering and Biotechnology
https://read.qxmd.com/read/38553812/evaluating-threshold-for-donor-fraction-cell-free-dna-using-clinically-available-assay-for-rejection-in-pediatric-and-adult-heart-transplantation
#27
JOURNAL ARTICLE
Shriprasad R Deshpande, Steven D Zangwill, Marc E Richmond, Steven J Kindel, Jacob N Schroder, Nunzio Gaglianello, David P Bichell, Mark A Wigger, Kenneth R Knecht, Phillip T Thrush, William T Mahle, Paula E North, Pippa M Simpson, Liyun Zhang, Mahua Dasgupta, Aoy Tomita-Mitchell, Michael E Mitchell
BACKGROUND: The aims of the study were to assess the performance of a clinically available cell-free DNA (cfDNA) assay in a large cohort of pediatric and adult heart transplant recipients and to evaluate performance at specific cut points in detection of rejection. METHODS: Observational, non-interventional, prospective study enrolled pediatric and adult heart transplant recipients from seven centers. Biopsy-associated plasma samples were used for cfDNA measurements...
May 2024: Pediatric Transplantation
https://read.qxmd.com/read/38550626/non-antigen-specific-immunoadsorption-is-a-risk-factor-for-severe-postoperative-infections-in-abo-incompatible-kidney-transplant-recipients
#28
JOURNAL ARTICLE
Laura Matuschik, Gabriel Seifert, Katrin Lammich, Philipp Holzner, Yakup Tanriver, Stefan Fichtner-Feigl, Gerd Walz, Johanna Schneider, Bernd Jänigen
ABO-incompatible (ABOi) living kidney transplantation (KTx) is an established procedure to address the demand for kidney transplants with outcomes comparable to ABO-compatible KTx. Desensitization involves the use of immunoadsorption (IA) to eliminate preformed antibodies against the allograft. This monocentric retrospective study compares single-use antigen-selective Glycosorb® ABO columns to reusable non-antigen-specific Immunosorba® immunoglobulin adsorption columns regarding postoperative infectious complications and outcome...
2024: Transplant International
https://read.qxmd.com/read/38548705/impact-of-preformed-donor-specific-antibodies-in-comparison-to-abo-incompatibility-in-living-donor-liver-transplantation-a-propensity-score-matched-analysis
#29
JOURNAL ARTICLE
Jiyoung Kim, Suk Kyun Hong, Jae-Yoon Kim, Jaewon Lee, Hyun Hwa Choi, Minseob Kim, Youngjin Kim, Su Young Hong, Jeong-Moo Lee, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh
BACKGROUND: Immunological factors play a pivotal role in the outcomes of solid organ transplantation. We aimed to elucidate the effects of donor-specific antibodies (DSAs) and ABO compatibility on living donor liver transplantation (LDLT) outcomes. METHODS: A retrospective analysis was conducted on 584 LDLT recipients from 2015 to 2020. The recipients were stratified into 3 groups: ABO-compatible recipients without DSAs (group 1), ABO-compatible recipients with DSAs (group 2), and ABO-incompatible recipients without DSAs (group 3)...
March 29, 2024: Transplantation
https://read.qxmd.com/read/38548057/molecular-diagnosis-of-antibody-mediated-rejection-evaluating-biopsy-based-transcript-diagnostics-in-the-presence-of-donor-specific-antibodies-but-without-microvascular-inflammation-a-single-center-descriptive-analysis
#30
JOURNAL ARTICLE
Dusan Harmacek, Lukas Weidmann, Kai Castrezana Lopez, Nicolas Schmid, Raphael Korach, Nicola Bortel, Seraina von Moos, Elena Rho, Birgit Helmchen, Ariana Gaspert, Thomas Schachtner
Biopsy-based transcript diagnostics may identify molecular antibody-mediated rejection (AMR) when microvascular inflammation (MVI) is absent. In this single-center cohort, biopsy-based transcript diagnostics were validated in 326 kidney allograft biopsies. A total of 71 histological AMR and 35 T cell-mediated rejection (TCMR) cases were identified as molecular AMR and TCMR in 55% and 63%, respectively. Among 121 cases without MVI (glomerulitis + peritubular capillaritis = 0), 45 (37%) donor-specific antibody (DSA)-positive and 76 (63%) DSA-negative cases were analyzed...
March 27, 2024: American Journal of Transplantation
https://read.qxmd.com/read/38548029/serum-il-6-predicts-risk-of-kidney-transplant-failure-independently-of-immunological-risk
#31
JOURNAL ARTICLE
Julius Friedmann, Antonia Schuster, Simone Reichelt-Wurm, Bernhard Banas, Tobias Bergler, Louisa Steines
Interleukin-6 (IL-6) is an important immune mediator and a target for novel antibody therapies. In this study, we aimed to determine whether serum IL-6 levels are associated with immunological risk, allograft rejection and outcomes in kidney transplant (Ktx) patients. We retrospectively analyzed the data of 104 patients who underwent Ktx at our center between 2011 and 2015. The patients were divided into high- and low-risk groups (n = 52 per group) based on panel reactive antibody (PRA) percentage ≥ 35%, the existence of pre-Ktx donor-specific antibodies (DSA), or a previous transplant...
March 26, 2024: Transplant Immunology
https://read.qxmd.com/read/38542404/effect-of-donor-age-on-endocrine-function-of-and-immune-response-to-ovarian-grafts
#32
JOURNAL ARTICLE
Monica A Wall, Mayara Garcia de Mattos Barbosa, Natalie Hanby, Michelle M Cai, Margaret Brunette, Despina I Pavlidis, Paula Arrowsmith, Ansen Q Tan, Marilia Cascalho, Ariella Shikanov
Premature loss of ovarian function (POI) is associated with numerous negative side effects, including vasomotor symptoms, sleep and mood disturbances, disrupted urinary function, and increased risks for osteoporosis and heart disease. Hormone replacement therapy (HRT), the standard of care for POI, delivers only a subset of ovarian hormones and fails to mimic the monthly cyclicity and daily pulsatility characteristic of healthy ovarian tissue in reproductive-aged individuals whose ovarian tissue contains thousands of ovarian follicles...
March 19, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38542163/expression-of-rejection-associated-transcripts-in-early-protocol-renal-transplant-biopsies-is-associated-with-tacrolimus-exposure-and-graft-outcome
#33
JOURNAL ARTICLE
Betty Chamoun, Irina B Torres, Alejandra Gabaldón, Thomas Jouvé, María Meneghini, José M Zúñiga, Joana Sellarés, Manel Perelló, Daniel Serón, Oriol Bestard, Francesc Moreso
Subclinical inflammation in protocol biopsies relates to tacrolimus exposure and human leukocyte antigen (HLA) matching. We aimed to characterize transcripts associated with rejection and tacrolimus exposure and the latter's association with transplant outcomes. We tested whether gene expression is associated with rejection using strictly normal protocol biopsies (n = 17) and biopsies with T cell-mediated rejection (TCMR) or antibody-mediated rejection (ABMR) according to Banff criteria (n = 12). Subsequently, we analyzed these transcripts in a set of 4-month protocol biopsies (n = 137) to assess their association with donor and recipient characteristics, the intensity of immunosuppression, and the graft outcome...
March 10, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38541826/plasma-mir-150-5p-in-renal-transplant-recipients-with-acute-antibody-mediated-rejection
#34
JOURNAL ARTICLE
Iván Zepeda-Quiroz, Carlos A Guzmán-Martín, Mario Peña-Peña, José D Juárez-Villa, Maria V Soto-Abraham, Miguel A Vázquez-Toledo, Rogelio F Jiménez-Ortega, Bernardo Moguel-González, Horacio Osorio-Alonso, Fausto Sánchez-Muñoz, César Flores-Gama
Background : Rejection continues to be the main cause of renal graft loss. Currently, the gold standard for diagnosis is an allograft biopsy; however, because it is time-consuming, costly, and invasive, the pursuit of novel biomarkers has gained interest. Variation in the expressions of miRNAs is currently considered a probable biomarker for the diagnosis of acute rejection. This study aimed to determine whether miR-150-5p in serum is related to microvascular damage in patients with acute antibody-mediated rejection (ABMR)...
March 11, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38540161/molecular-microscope-diagnostic-system-in-patients-after-kidney-transplantation-first-experience
#35
Monika Beliančinová, Patrícia Kleinová, Tímea Blichová, Matej Vnučák, Karol Graňák, Katarína Kajová Macháleková, Ivana Dedinská
BACKGROUND: The diagnosis of graft rejection relies on the identification of donor-specific antibodies along with histological findings. Borderline changes are particularly challenging, representing non-rejection findings in up to 70% of cases. The analysis aimed to compare the results of histopathological conclusions with the findings from examination using a molecular microscope, which assesses gene expression (whole-genome microarray chip technology). METHODS: Molecular microscope examination (MMDx) was applied to twelve patients (six men and six women) who underwent either indication or protocol graft biopsy...
February 29, 2024: Biomedicines
https://read.qxmd.com/read/38537484/tacrolimus-intra-patient-variability-measures-and-its-associations-with-allograft-clinical-outcomes-in-kidney-transplantation
#36
REVIEW
Wenmin Xie, Shupan Fan, Ruolin Liu, Wencheng Yan, Chengxin Su, Kaile Zheng, Xuebin Wang, Zhuo Wang
AIMS: Tacrolimus (Tac) is commonly prescribed in solid organ transplantation to prevent immune-mediated damage to the graft. However, its pharmacokinetics show substantial variability between and within patients. Intra-patient variability of tacrolimus (Tac-IPV) has emerged as a novel marker to predict transplant outcomes. Numerous studies report varying associations between Tac-IPV and clinical outcomes, with Tac-IPV measures showing wide discrepancies among these studies. This inconsistency could be a significant factor that influences the various outcomes reported in different studies...
March 21, 2024: Transplantation Reviews
https://read.qxmd.com/read/38528753/histopathology-mrna-expression-profile-and-donor-derived-cell-free-dna-for-assessment-of-rejection-in-pediatric-heart-transplantation
#37
JOURNAL ARTICLE
Conor P O'Halloran, Paul Tannous, Nicoleta C Arva, Philip T Thrush, Michael Monge, Anna Joong, Defne A Magnetta
BACKGROUND: The relationship between histopathologic and molecular ("MMDx"®) assessments of endomyocardial biopsy (EMB) and serum donor-derived cell-free DNA (ddcfDNA) in acute rejection (AR) assessment following pediatric heart transplantation (HT) is unknown. METHODS: EMB sent for MMDx and histopathology from November 2021 to September 2022 were reviewed. MMDx and histopathology results were compared. DdcfDNA obtained ≤1 week prior to EMB were compared with histopathology and MMDx results...
May 2024: Pediatric Transplantation
https://read.qxmd.com/read/38527588/redefining-the-molecular-rejection-states-in-3230-heart-transplant-biopsies-relationships-to-parenchymal-injury-and-graft-survival
#38
JOURNAL ARTICLE
Philip F Halloran, Katelynn Madill-Thomsen, Arezu Z Aliabadi-Zuckermann, Martin Cadeiras, Marisa G Crespo-Leiro, Eugene C Depasquale, Mario Deng, Johannes Gökler, Shelley Hall, Aayla Jamil, Daniel H Kim, Jon Kobashigawa, Peter Macdonald, Vojtech Melenovsky, Jignesh Patel, Luciano Potena, Keyur Shah, Josef Stehlik, Andreas Zuckermann
The first-generation Molecular Microscope® (MMDx) system for heart transplant endomyocardial biopsies used expression of rejection-associated transcripts (RATs) to diagnose T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR) but also detected acute injury. However, the ideal system should detect rejection without being influenced by injury, to permit analysis of the relationship between rejection and parenchymal injury. To achieve this, we developed a new rejection classification in an expanded cohort of 3230 biopsies: 1641 from INTERHEART (ClinicalTrials...
March 23, 2024: American Journal of Transplantation
https://read.qxmd.com/read/38524599/single-cell-and-bulk-rna-sequencing-highlights-the-role-of-m1-like-infiltrating-macrophages-in-antibody-mediated-rejection-after-kidney-transplantation
#39
JOURNAL ARTICLE
Qidan Pang, Liang Chen, Changyong An, Juan Zhou, Hanyu Xiao
BACKGROUND: Antibody-mediated rejection (ABMR) significantly affects transplanted kidney survival, yet the macrophage phenotype, ontogeny, and mechanisms in ABMR remain unclear. METHOD: We analyzed post-transplant sequencing and clinical data from GEO and ArrayExpress. Using dimensionality reduction and clustering on scRNA-seq data, we identified macrophage subpopulations and compared their infiltration in ABMR and non-rejection cases. Cibersort quantified these subpopulations in bulk samples...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38520670/a-phase-1-2-study-of-pepinemab-in-children-adolescents-or-young-adults-with-recurrent-or-refractory-solid-tumors-a-children-s-oncology-group-consortium-report-advl1614
#40
JOURNAL ARTICLE
Emily Greengard, Robin Williams, Branden Moriarity, Xiaowei Liu, Charles G Minard, Joel M Reid, Terrence Fisher, Elizabeth Evans, Desa Rae Pastore, Maurice Zauderer, Stephan Voss, Elizabeth Fox, Brenda J Weigel
PURPOSE: Pepinemab, a humanized IgG4 monoclonal antibody, targets the SEMA4D (CD100) antigen to inhibit binding to its high-affinity receptors (plexin B1/PLXNB1, plexin B2/PLXNB2) and low-affinity receptor (CD72). SEMA4D blockade leads to increased cytotoxic T-cell infiltration, delayed tumor growth, and durable tumor rejection in murine tumor models. Pepinemab was well tolerated and improved T cell infiltration in clinical studies in adults with refractory tumors. SEMA4D was identified as a strong candidate proto-oncogene in a model of osteosarcoma...
March 23, 2024: Pediatric Blood & Cancer
keyword
keyword
169272
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.